BBus FCPA - Telix Pharmaceuticals Group Officer
| TLX Stock | 17.60 0.30 1.73% |
Executive
BBus FCPA is Group Officer of Telix Pharmaceuticals Limited
| Age | 59 |
| Phone | 61 3 9093 3855 |
| Web | https://telixpharma.com |
Telix Pharmaceuticals Management Efficiency
The company has Return on Asset of 0.0797 % which means that on every $100 spent on assets, it made $0.0797 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.2049 %, implying that it generated $0.2049 on every 100 dollars invested. Telix Pharmaceuticals' management efficiency ratios could be used to measure how well Telix Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Leiden MBA | Tscan Therapeutics | N/A | |
| Heather Savelle | Tscan Therapeutics | N/A | |
| Sam Faucette | Old Dominion Freight | N/A | |
| Brian Lloyd | Merit Medical Systems | 63 | |
| Ann Hargraves | Tscan Therapeutics | N/A | |
| Zoran JD | Tscan Therapeutics | 54 | |
| Kimberly Maready | Old Dominion Freight | 53 | |
| Mark Butler | Merit Medical Systems | N/A | |
| Jim Murray | Tscan Therapeutics | N/A | |
| Cagan Gurer | Tscan Therapeutics | N/A | |
| Brian JD | Merit Medical Systems | 64 | |
| Steven Hartsell | Old Dominion Freight | 56 | |
| Rasmus Hoffmann | Torm PLC Class | 48 | |
| Liv Kjr | Torm PLC Class | 40 | |
| Jesper Jensen | Torm PLC Class | 56 | |
| Sarah Comstock | Merit Medical Systems | N/A | |
| Jason Amello | Tscan Therapeutics | 56 | |
| Lars Christensen | Torm PLC Class | 59 | |
| JoAnne Alkire | Merit Medical Systems | N/A | |
| MPH MD | Tscan Therapeutics | 48 | |
| Mikael Larsen | Torm PLC Class | N/A | |
Management Performance
| Return On Equity | 0.2 | ||||
| Return On Asset | 0.0797 |
Telix Pharmaceuticals Leadership Team
Elected by the shareholders, the Telix Pharmaceuticals' board of directors comprises two types of representatives: Telix Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Telix. The board's role is to monitor Telix Pharmaceuticals' management team and ensure that shareholders' interests are well served. Telix Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Telix Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Kevin MBA, Chief Medicine | ||
| Richard MBA, Chief Therapeutics | ||
| BSc BSc, Chief Scientist | ||
| Lena LLB, Group Counsel | ||
| Christian Davis, EMEA Marketing | ||
| Darren PharmD, Group Officer | ||
| Darren Patti, Group Officer | ||
| Craig Ulrick, Chief Officer | ||
| MBA LLB, Chief International | ||
| MBA MD, Group Officer | ||
| Michelle Hickey, Senior Operations | ||
| LLB BSc, Group Secretary | ||
| Thomas Fromm, Vice Sales | ||
| Dov Gardin, Sustainability Risk | ||
| Andreas MD, Chief Advisor | ||
| BEng DPhil, MD, CoFounder | ||
| Meredith BDES, Senior Culture | ||
| Kyahn BA, Senior Relations | ||
| BBus FCPA, Group Officer | ||
| Mary Jessel, Senior Affairs |
Telix Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Telix Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.2 | ||||
| Return On Asset | 0.0797 | ||||
| Profit Margin | 0.08 % | ||||
| Operating Margin | 0.09 % | ||||
| Current Valuation | 5.2 B | ||||
| Shares Outstanding | 334.72 M | ||||
| Number Of Shares Shorted | 20.33 K | ||||
| Price To Book | 20.71 X | ||||
| Price To Sales | 8.09 X | ||||
| Revenue | 783.21 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Telix Stock Analysis
When running Telix Pharmaceuticals' price analysis, check to measure Telix Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Telix Pharmaceuticals is operating at the current time. Most of Telix Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Telix Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Telix Pharmaceuticals' price. Additionally, you may evaluate how the addition of Telix Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.